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The substantia nigra is among the richest pro-dynorphin terminal field 
regions in the rat brain. We therefore contrasted processing in this area to 
the known processing in the posterior pituitary. Fractionation of acid 
extracts of the posterior pituitary by gel filtration followed by analysis by 
radioimmunoassay indicated that the molar ratio of dynorphin A(l-17) to 
dynorphin A(l-8) averaged 1:2. The levels of dynorphin A-related end products 
t0 a-neo-endorphin and bridge peptide (a 2K nonopioid end product of 
pro-dynorphin) were approximately equimolar; however, the levels of dynorphin 
B-sized material were 50% lower than dynorphin A levels. Similar analyses of 
acid extracts of the substantia nigra also indicated that the levels of 
dynorphin A, a-neo-endorphin, and bridge pept ide were approximately 
equimolar. In this terminal field the levels of dynorphin B-sized material 
were approximately 60% lower than dynorphin A. A striking feature of the 
nigral system was that the molar ratio of dynorphin A(l-17) to dynorphin 
A(l-8) averaged 1:16. Thus, in the nigra, dynorphin A(l-17) is primarily a 
biosynthetic intermediate rather than as an end product. 
INTRODUCTION 
Pro-dynorphin is the common precursor for three opioid peptides: dynorphin 
A, dynorphin B, and wneo-endorphin (1). In some tissue, dynorphin A(l-17) 
can be cleaved to yield dynorphin A( l-8), and a-neo-endorphin can be 
converted to fi -neo-endorphin (2). Finally, these opioid peptides could also 
potentially be proteolytically cleaved to yield leucine enkephalin. Several 
recent studies indicate that some of these post-translational processing 
events occur in the posterior pituitary as well as in different regions of the 
brain (2,3,4). However, a drawback to studying these processing events by 
analysis of large brain regions, is the inevitable mixing of cell body and 
terminal field regions. To avoid this we have focused on the steady state 
levels of pro-dynorphin-related end products in two clearly defined terminal 
field regions: the posterior pituitary and the substantia nigra. Furthermore, 
our understanding of the processing of pro-dynorphin-related opioid peptides 
in the rodent brain has been greatly aided by the isolation of bridge peptide, 
a nonopioid end product of pro-dynorphin which represents the 2K polypeptide 
fragment positioned between ct-neo-endorphin and dynorphin A in the seqeunce 
of porcine pro-dynorphin (Dores, Houghton, Watson and Akil, in preparation). 
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MATERIALS AND METHODS 
For these experiments, adult male Sprague Dawley rats (average wet weight: 
250 gm) were sacrificed in groups of 5 to 10 and posterior pituitaries (mean 
wet weight: 1.6 LO.1 mg) and substantia nigra (mean wet weight: 10.5 0.2 mg) 
were pooled. Experiments were done in triplicate. The tissues were extracted 
in 10 volumes of acetone: 0.1 N HCl (3:l) as described previously (5). The 
extracts were concentrated and redissolyed in 500 1 of 10% formic acid buffer 
and fractionated by gel filtration on a Sephadex G-50 column ( 1 x 54 cm; 
Pharmacia) equilibrated in 10% formic acid which contained 100 pg/ml bovine 
serum albumin. The column was eluted with a flow rate of 1.5 ml/hr and 600 pl 
fractions were collected. The void volume was marked with bovine serum albumin 
and the total volume was marked with 2, B-mercaptoethanol. Following gel 
filtration, aliquots of fractions were concentrated under vacuum (Savant) and 
analyzed by radioimmunoassay. Recoveries averaged 82%. 
Several radioimmunoassays to various end products of pro-dynorphin were 
used in this study. Radioimmunoassays specific for dynorphin A(l-17), 
dynorphin A(l-8), dynorphin B, and o-neo-endorphin were done as described by 
Cone et al. (4). The specificities and sensitivities of these antisera are 
described in Dores et @. (5). Antis erum against synthetic porcine bridge 
peptide(l-21) (1) was generated in rabbits and was used at a final dilution of 
1:15,000, with an average midpoint of 75 fmol/tube. 
In order to assay each column run for all the potential 
pro-dynorphin-related products, the following fractions were assayed: for 
dynorphin A(l-17), #42-50; for dynorphin A(l-8), 852-60; for dynorphin B, 
f/48-53; for a-neo-endorphin, 150-55; and for bridge peptide, 642-50. 
RESULTS AND DISCUSSION 
The results of analyses of extracts of rat posterior pituitary are 
summarized in Fig. 1 and Table 1. Dynorphin A(l-17)-sized material and 
dynorphin A(l-8)-sized material represented the major forms of dynorphin A in 
these extracts. On the average the molar ratio of dynorphin A(l-17) to 
dynorphin A(l-8) in this terminal field was 1:2. These results are in general 
agreement with previous studies on this terminal field (2,3,4). As shown in 
Table 1, the levels of bridge peptide-sized material are approximately 
equimolar with both dynorphin A and a-neo-endorphin; thus, it appears that 
this polypeptide is a major nonopioid end product of pro-dynorphin 
post-translational processing in this terminal field. By contrast, the levels 
of dynorphin B-sized material were 50% lower than Dynorphin A levels. 
Analyses of rat substantia nigra extracts are summarized in Fig. 2 and 
Table 1. As seen in the posterior pituitary, the levels of dynorphin A, 
o-neo-endorphin, and bridge peptide were equimolar. A striking feature of 
the substantia nigra is the low levels of dynorphin A(l-17)-related material 
(Fig. 2). In this terminal field the major dynorphin A product is dynorphin 
A(l-8) which is present in a 16 fold higher molar concentration than dynorphin 
A(l-17). Thus, dynorphin A(l-17) appears to function as a biosynthetic 
intermediate, rather than an end product. The levels of dynorphin B, while 
higher than dynorphin A(l-17), are on the average 60 % lower than dynorphin 
A(l-8) or a -neo-endorphin. A recent study has suggested that the opioid 
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peptides derived from pro-dynorphin may be converted to leucine enkephalin in 
the substantia nigra of the rat (6). Collectively, these results would 
indicate that leucine enkephalin could conceivalby be formed from the cleavage 
of dynorphin B, but not from dynorphin A or a-neo-endorphin. Thus the 
production of leucine enkephalin could represent a minor pathway, but not a 
major pathway in the post-translational processing of pro-dynorphin in the 
substantia nigra of the rat. Furthermore, the levels of leumorphin (7), the 
COW-terminally extended form of dynorphin B( l-13), need to be determined 
before any definitive statements can be made on the production of leucine 
enkephalin from pro-dynorphin. 
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Fig. 1. Sephadex G-50 profile of rat posterior pituitary. Ten 
posterior pituitaries were extracted and chromatographed as 
described in METHODS. The solid lines represent dynorphin 
A(l-17)-related material, and the dashed line represents dynorphin 
A( 1-8)-related material. 
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Fig. 2. Sephadex G-50 Profile of rat substantia nigra. Five 
substantia nigra were pooled and extracted as described in METHODS. 
The solid line represents dynorphin A( l-17) related material, and 
the dashed line represents dynorphin A(l-8)-related material. 
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TABLE 1 
fmol/ mg wet weight 
Peptide Posterior Pituitary Substantia Nigra 
Dynorphin A(l-17) 630 + 1901 20 + 5 
Dynorphin A(l-8) 1190 + 190 320 +-20 
Dynorphin B 940 7 380 100 T 10 
+Neo-endorphin 1250 + 310 290 T 30 
Bridge Peptide 1440 + 130 240 7 20 
' MEAN + S.E.M. (n=3) 
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